Pharmacists in non-oncology settings and not involved in direct cancer care of patients are more commonly encountering patients who are receiving or who have received an immune checkpoint inhibitor (ICI). Timely recognition and management of immune-related adverse events (irAEs) is needed to avoid progression of mild or moderate irAEs to more severe events and to avoid disruptions in ICI treatment. It is crucial that pharmacists working as part of a multidisciplinary team recognize the signs and symptoms of irAEs and triage patients experiencing these reactions to appropriate care levels based on irAE severity. Pharmacists should implement guideline-directed treatment strategies for irAE management and ensure patients are connected to their oncology treatment team for appropriate outpatient monitoring.
In this CME Outfitters BriefCase, expert faculty will guide learners through a patient case involving an initial presentation of an irAE within the ambulatory care setting. This program will provide guidance to pharmacists working within a multidisciplinary care team on strategies for the triage and initial guideline-directed management of patients with a suspected irAE.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Pharmacists in outpatient, ambulatory, or community care settings.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Reynolds reports the following financial relationships:
Research Support: Project Data Sphere (a non-profit company)
Stock Shareholder (ownership interest): Biogen
Other Financial or Material Support: Teledoc Health, Inc.
Dr.Castner reports no financial relationships to disclose.
Dr. Dougan reports the following financial relationships:
Advisory Board: Cerberus Therapeutics and Veravas, Inc.
Consultant: Aditum Bio; Asher Biotherapeutics, Inc.; AzurRx BioPharma, Inc.; Eli Lilly and Company; Foghorn Therapeutics; Genentech, Inc.; Generate Biomedicines; Mallinckrodt Pharmaceuticals; Moderna, Inc.; ORIC Pharmaceuticals, Inc.; Palleon Pharmaceuticals; Partner Therapeutics, Inc.; Sorriso Pharmaceuticals; and SQZ Biotechnologies Company
Research Support: Eli Lilly and Company
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).